Abstract
BackgroundBiosimilars are highly similar to reference products and can help in reducing the financial burden and medication underutilization while still being comparable to reference products in treating rheumatic diseases[1].ObjectivesThe objective...
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have